ADAM17

ADAM17

ADAM17 Overview

Molecule Name
Disintegrin and metalloproteinase domain-containing protein 17
Synonyms
ADAM17,TACE,CD156b
Drug Development Progress
Drugs in Clinical Trials2
Approved Drugs0
Highest Development StagePhase 1 Clinical
Target Synonym
EC:3.4.24.86,ADAM17 Protein,ADAM 17,Snake venom-like protease,CSVP,CD156b,ADAM17,ADAM Metallopeptidase Domain 17,TNF-Alpha Convertase,TACE,TNF-Alpha Converting Enzyme,TNF-Alpha-Converting Enzyme,CD156b Antigen,EC 3.4.24.86,NISBD1,NISBD,Disintegrin and metalloproteinase domain-containing protein 17,Tumor Necrosis Factor, Alpha, Converting Enzyme,ADAM Metallopeptidase Domain 18,ADAM18
Background
Disintegrin and metalloproteinase domain-containing protein 17 (ADAM17), a member of the ADAM protein family of disintegrins and metalloproteases, is also known as TNF-alpha convertase, TNF-alpha-converting enzyme and CD156b, which contains one disintegrin domain and one peptidase M12B domain. ADAM17 can cleave the membrane-bound precursor of TNF-alpha to its mature soluble form. ADAM17 is also responsible for the proteolytical release of soluble JAM3 from endothelial cells surface (By similarity) and proteolytic release of several other cell-surface proteins, including p75 TNF-receptor, interleukin 1 receptor type II, p55 TNF-receptor, transforming growth factor-alpha, L-selectin, growth hormone receptor, MUC1 and the amyloid precursor protein. Furthermore, ADAM17 acts as an activator of Notch pathway by mediating cleavage of Notch, generating the membrane-associated intermediate fragment called Notch extracellular truncation.

ADAM17 Product List

No Data
You Have Viewed 0 Of 0 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
AderbasibINCB-7839; INC-B007839; INCB-007839Phase 1 ClinicalIncyte Corp
Astrocytoma; Breast Neoplasms; Diffuse Intrinsic Pontine Glioma; Glioblastoma; Glioma; Lymphoma, Large B-Cell, Diffuse; Neoplasms; Oligodendroglioma; Solid tumours
Details
ORYN-1001ORTD-1; ORYN-1001Phase 1 ClinicalOryn Therapeutics Llc
Arthritis, Rheumatoid; Coronavirus Disease 2019 (COVID-19)
Details